• Unrivaled resolution of structural variations, rearrangements, and exon duplicates
• Flexible workflow
• Combined breadth and depth
• Designed for biomarker analysis in clinical trials, treatment monitoring, and acquisition of drug resistance with a single blood draw
Available in RUO and CLIA-validated assay
From a single sample, we provide low-pass whole genome sequencing (LP-WGS) data combined with broader coverage using WES and/or in-depth profiling using PredicineCARE™ or PredicineATLAS™ focused pan cancer panels, based on tumor fraction from the sample.
Whole blood
Plasma
cfDNA
5-10ml whole blood
2-5ml plasma
5-30ng cfDNA
LP-WGS: 2 weeks
Panel: 3 weeks
WES: 4 weeks
We offer pilot program grants to select biopharma and academic partners to empower translational research and clinical studies. To initiate a study, contact us via the form below.
If you have any questions or need assistance, complete this form and we will respond within 24 hours.